Drugs / TQB2029
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06700395 | Nov 2024 → Mar 2026 overdue | plasma cell myeloma | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB2029 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06700395 ↗ |
| Target | GPRC5D | “targeting G Protein-Coupled Receptor, Class C, Group 5, Member D (GPRC5D)” NCT06700395 ↗ |